Dr. Mik Rinne on the First Promising CDK2 Inhibitor in Combination to Treat HR+/HER2- Breast Cancer

Blueprint Medicines recently shared new data regarding its CDK2 inhibitor, BLU-222, in patients with HR+/HER2- breast cancer. The data, which mark the first promising clinical results for a CDK2 inhibitor in combination with an approved CDK4/6 inhibitor, were presented at the 2024 American Society of Clinical Oncology Annual Meeting. Dr. Mik Rinne, vice president of clinical development at Blueprint, spoke to DocWire News about the exciting findings of this trial and the implications in the fight against breast cancer.